Bavarian Nordic A/S entered new contract with an undisclosed APAC country for the supply of 350,000 doses of its non-replicating JYNNEOS® smallpox/monkeypox vaccine. Deliveries and all revenues under this contract will occur in 2023 and thus the order has no impact on the financial guidance for this year. Bavarian Nordic signed its first supply contract with this country earlier this summer to ensure deliveries in 2022, which have recently started.

With this order, together with previously announced orders from the US, Canada and other countries, Bavarian Nordic now has significant orders of smallpox/monkeypox vaccines, providing a robust basis for 2023.